B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches | Leukemia
Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma | Journal of Clinical Oncology
Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? | Leukemia
Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma | PNAS
Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector: Molecular Therapy
CAR T-cell therapy in multiple myeloma: more room for improvement | Blood Cancer Journal
Effective anti-BCMA retreatment in multiple myeloma - ScienceDirect
γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma - ScienceDirect
T cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells: Molecular Therapy - Methods & Clinical Development
Cancers | Free Full-Text | Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma
CAR T-cell therapy in multiple myeloma: more room for improvement | Blood Cancer Journal
Frontiers | Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
CIMB | Free Full-Text | sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies - ScienceDirect
Improving Multiple Myeloma CAR T-Cell Therapy - NCI
Therapeutic options for targeting myeloma epitopes, in this case, BCMA;... | Download Scientific Diagram
VisualAbstract: Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma | 2 Minute Medicine
Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell Leukemia - ScienceDirect
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma | Haematologica
Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma | Nature Communications
Accelerating clinical-scale production of BCMA CAR T cells with defined maturation stages: Molecular Therapy - Methods & Clinical Development
Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma | bioRxiv
Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? | Leukemia
B cell maturation antigen (BCMA)-based immunotherapies with multiple... | Download Scientific Diagram
